Precision medicine in bronchiectasis

Thomas Pembridge, James D. Chalmers (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
21 Downloads (Pure)

Abstract

Bronchiectasis, due to its highly heterogenous nature, requires an individualised approach to therapy. Patients experience symptoms and exacerbations driven by a combination of impaired mucociliary clearance, airway inflammation and airway infection. Treatment of bronchiectasis aims to enhance airway clearance and to address the underlying causes of inflammation and infection susceptibility. Bronchiectasis has multiple causes and so the pathophysiology leading to individual symptoms and exacerbations are different between individuals. Standardised investigations are recommended by international guidelines to identify the underlying causes of bronchiectasis. The process of identifying the underlying biology within an individual is called “endotyping” and is an emerging concept across chronic diseases. Endotypes that have a specific treatment are referred to as “treatable traits” and a treatable traits approach to managing patients with bronchiectasis in a holistic and evidence-based manner is the key to improved outcomes. Bronchiectasis is an area of intense research. Endotyping allows identification of subsets of patients to allow medicines to be tested differently in the future where trials, rather than trying to achieve a “one size fits all” solution, can test efficacy in subsets of patients where the treatment is most likely to be efficacious.

Original languageEnglish
Article number210119
Pages (from-to)1-16
Number of pages16
JournalBreathe
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Dec 2021

Fingerprint

Dive into the research topics of 'Precision medicine in bronchiectasis'. Together they form a unique fingerprint.

Cite this